Abstract
The significance of the human multidrug resistance gene (MDR1) G1199A polymorphism, resulting in a Ser400Asn modification in P-glycoprotein (P-gp), remains unclear. We have developed stable recombinant LLC-PK1 epithelial cells expressing either MDR1wt or MDR11199 to evaluate functional consequences of G1199A [N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide]. P-gp activity observed in MDR1wt and MDR11199 cells was completely inhibited in the presence of the specific P-gp inhibitor GF120918. Comparable expression of mRNA and protein in the MDR1-expressed cells and correct localization of P-gp in the apical membrane of recombinant cells was verified. Mean intracellular rhodamine-123 (R123) accumulation, measured by flow cytometry, was approximately 4.75-fold higher in MDR11199 recombinant cells than MDR1wt cells. Cytotoxicity studies have shown that MDR1wt and MDR11199 cells exhibited similar resistance, as measured by EC50 values, to doxorubicin (155 ± 68 versus 120 ± 32 nM); however, MDR11199 cells were more resistant to vinblastine (1.41 ± 0.51 versus 15.7 ± 4.0 nM; p < 0.001) and vincristine (1.18 ± 0.56 versus 3.41 ± 1.47 nM; p < 0.05). The apparent transepithelial permeability ratios of R123 in MDR1wt and MDR11199 cells were 3.54 ± 0.94 and 2.02 ± 0.51 (p < 0.05), respectively. Therefore, the G1199A polymorphism alters the efflux and transepithelial permeability of a fluorescent substrate and sensitivity to select cytotoxic agents, which may influence drug disposition and therapeutic efficacy of some P-gp substrates.
Footnotes
-
This study was supported in part by National Institutes of Health Grants GM62883, AI52663, NS39178, AI31854, ES07033, and HL56548. E.L.W. is a recipient of the National Institutes of Health Pharmaceutical Sciences Training Grant (GM07750) and the William E. Bradley Fellowship in Pharmaceutics.
-
doi:10.1124/jpet.104.065383.
-
ABBREVIATIONS:MDR1, multidrug resistance gene; P-gp, P-glycoprotein; SNP, single nucleotide polymorphism; PCR, polymerase chain reaction; PBS, phosphate-buffered saline; BSA, bovine serum albumin; HBSS, Hanks' balanced salt solution; PE, phycoerythrin; R123, rhodamine-123.
- Received January 13, 2004.
- Accepted April 20, 2004.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|